{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f", "Q4", 322897, "NAHIGIAN STRATEGIES, LLC", 187028, "TEVA PHARMACEUTICALS USA INC", 2014, "fourth_quarter", "2015-01-14T10:29:03.693000-05:00", 45000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f/\", \"filing_uuid\": \"60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f\", \"filing_type\": \"Q4\", \"filing_type_display\": \"4th Quarter - Report\", \"filing_year\": 2014, \"filing_period\": \"fourth_quarter\", \"filing_period_display\": \"4th Quarter (Oct 1 - Dec 31)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"45000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"KENNETH NAHIGIAN\", \"dt_posted\": \"2015-01-14T10:29:03.693000-05:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"1001 19th Street, Suite 1200\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Arlington\", \"registrant_state\": \"VA\", \"registrant_zip\": \"22209\", \"registrant\": {\"id\": 322897, \"url\": \"https://lda.senate.gov/api/v1/registrants/322897/\", \"house_registrant_id\": null, \"name\": \"NAHIGIAN STRATEGIES, LLC\", \"description\": \"Coalition of mothers advocating for access to therapies for epilepsy\", \"address_1\": \"1001 19th Street, Suite 1200\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"Arlington\", \"state\": \"VA\", \"state_display\": \"Virginia\", \"zip\": \"22209\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"KENNETH NAHIGIAN\", \"contact_telephone\": \"+1 703-567-6996\", \"dt_updated\": \"2022-04-06T16:08:31.636334-04:00\"}, \"client\": {\"id\": 187028, \"url\": \"https://lda.senate.gov/api/v1/clients/187028/\", \"client_id\": 24, \"name\": \"TEVA PHARMACEUTICALS USA INC\", \"general_description\": \"Pharmaceutical Manufacturer\", \"client_government_entity\": false, \"client_self_select\": false, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"PA\", \"ppb_state_display\": \"Pennsylvania\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2009-06-15\"}, \"lobbying_activities\": [{\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"Issues related to generic drug exclusivity.\", \"foreign_entity_issues\": \"Teva Pharmaceuticals is an Israeli-based company.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 49676, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"KENNETH\", \"nickname\": null, \"middle_name\": \"ROBERT\", \"last_name\": \"NAHIGIAN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f"], "units": {}, "query_ms": 1.2682939413934946, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}